secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuo Therapeutics, Inc. (AURX)
CIK:        0001091596
Form:       8-K
Filed at:   2026-08-17T11:55:11+00:00
Accession:  0001437749-26-028109
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuo Therapeutics Q2 2026 revenue up >150% YoY; operating loss narrows to $167K
------------------------------------------------------------------------------

- Q2 2026 total revenues ~$1.77M, up >150% YoY; H1 2026 revenues ~$3.07M, also up >150%.
- Q2 product revenues up 38% sequentially; Aurix brand up >30% sequentially.
- Q2 net operating loss ~$167K, improved ~$280K vs Q1 2026.
- Amended loan: interim funding $675K, $325K remaining under $2M commitments; option to increase borrowings Sept 30, 2026.
- Reimbursement fee milestone achieved under Smith+Nephew distribution agreement; payment expected this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/0001437749-26-028109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/aurx20260816c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-028109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer